Figure 2. Nrf2 activation is required for tHSCs-induced DIgR2 expression in mDCs. The stable bone marrow-derived dendritic cells (mDCs), with Nrf2 shRNA (“sh-Nrf2”) or Nrf2 KO construct (“ko-Nrf2”), as well as the parental control mDCs (“Pare”), were co-cultured with tumor HSCs (tHSCs; mDCs to tHSCs ratio, 20: 1) for applied time, expression of listed genes was shown (A and B). Expression of listed genes in stable mDCs with Keap1 shRNA (“sh-Keap1”) or the parental control mDCs (“Pare”) was shown (C and D). Control mDCs were treated with 3H-1,2-dithiole-3-thione (D3T, 25 μM), MIND4-17 (10 μM) or vehicle control (0.25% DMSO) for applied time, listed genes were shown (E and F). Data are presented as the mean ± standard deviation (n=5). “Ctrl” stands for mDCs only. * P < 0.05 vs. “Pare” cells (A and C). * P < 0.05 vs. “DMSO”-treated cells (E). The experiments in this figure were repeated three times, and similar results were obtained.